PCOS Overdiagnosis: Are We Unnecessarily Labeling Women?

Initially, PCOS diagnosis, first identified in the 1930s, focused on specific symptoms like amenorrhea (absence of menstruation) and infertility linked to multiple ovarian cysts. Over time, criteria have broadened. The 1990 National Institutes of Health (NIH) criteria required both irregular periods and signs of high androgens. The 2003 Rotterdam criteria expanded this to include two of three criteria: irregular periods, signs of high androgens, or polycystic ovaries on ultrasound. Finally, the 2006 Androgen Excess and PCOS Society emphasized hyperandrogenism as a primary factor, alongside either irregular periods or polycystic ovaries. This shift raises concerns about potential overdiagnosis, especially with the broader Rotterdam criteria.

There are three main diagnostic criteria: the 1990 NIH criteria, the 2003 Rotterdam criteria, and the 2006 Androgen Excess and PCOS Society criteria. The NIH criteria require both oligo-ovulation/anovulation and clinical/biochemical signs of hyperandrogenism. The Rotterdam criteria require two out of three: oligo-ovulation/anovulation, hyperandrogenism, or polycystic ovaries on ultrasound, potentially leading to broader diagnoses. The Androgen Excess and PCOS Society criteria emphasize hyperandrogenism along with either irregular periods or polycystic ovaries. The expansion, especially with the Rotterdam criteria, has led to more diagnoses but also to debate about whether these wider criteria accurately reflect the condition's impact on women's health, potentially leading to overdiagnosis and unnecessary anxiety.

Concerns about overdiagnosis stem from the expanding diagnostic criteria, particularly the 2003 Rotterdam criteria. These broader criteria may include women with milder symptoms or those who may not experience the same long-term health risks. Overdiagnosis can lead to unnecessary labeling, potentially causing anxiety and prompting medical interventions that may not be required. This can create unnecessary concern, especially among younger women, without necessarily improving health outcomes. The core of the debate is whether the increased prevalence of PCOS diagnoses genuinely translates to better health for women, or if it introduces more harm than good through misdiagnosis.

A broader diagnostic approach, exemplified by the 2003 Rotterdam criteria, carries potential downsides, primarily concerning the possibility of unnecessary labeling and anxiety. By including a wider range of symptoms, the criteria may identify women who have milder forms of the condition or who might not experience the long-term health risks typically associated with PCOS. This could lead to women receiving a diagnosis that may not be entirely accurate or reflect the severity of their condition. This can lead to unnecessary concern and potentially prompt medical interventions. This wider net might not always translate into improved health outcomes, and can inadvertently create psychological stress and increase the burden of healthcare for women.

To avoid overdiagnosis, healthcare professionals should adopt a case-by-case approach, carefully considering an individual's symptoms, risk factors, and concerns. This might involve a slower or delayed diagnostic process, particularly in adolescents and young women with milder symptoms. Open communication and shared decision-making are crucial to ensure the best possible care, tailored to individual needs. This approach helps to balance the benefits of early detection with the potential harms of unnecessary labeling and medical interventions, allowing women to receive appropriate care without the added burden of an inaccurate diagnosis.